|
市場調查報告書
心臟病之診斷：技術與市場的主要發展
Cardiovascular Diagnostics: Key Developments in Technologies and Markets
|
本報告已在2011年07月19日停止出版。
由於人口快速高齡化導致心臟病發生／罹患率增加，因此早期發現與治療就更形重要。 因遺傳基因領域調查獲高度評價的美國調查公司 Insight Pharma Reports （總公司：麻薩諸塞州）， 針對心血管圖像/體外診斷技術的最新趨勢及發展進行調查分析，並發行了報告書 "Cardiovascular Diagnostics: Key Developments in Technologies and Markets" 。
本報告書內容包括：非侵入性血管造影法、新的心臟病生物標記、核能醫學領域中新興放射性醫藥品之開發、磁氣共振顯像法（MRI）等顯像法之進步、動脈中瘀血顯影開發之初期階段、心臟病治療方法之新趨勢等，內容綱要摘記如下。
第1章 心臟病的背景趨勢
- 心臟病的統計
- 冠狀動脈心臟病
- 瘀血性心因猝死
- 高血壓
- 腦中風
- 心律不整
- 其他的心臟疾病
- 心臟病治療方法診斷之預測
第2章 心血管圖像
第3章 生物標記與心臟病診斷
- 判定冠狀動脈疾病（CAD）風險用之生物標記
- 判定CAD風險用生物標記之解說
- 醫療／經濟層面的影響
- 競爭與展望
- 診斷急性冠狀症候群（ACS）用之生物標記
- 既有ACS生物標記之解說
- 未來可能的ACS生物標記
- 醫療／經濟層面的影響
- 競爭與展望
- 瘀血性心因猝死生物標記
- 血栓病生物標記
- 生物標記與基因標記之解說
- 醫療／經濟層面的影響
- 競爭與展望
- 腦中風未來可能的生物標記
- 腦中風之潛在生物標記之解說
- 醫療／經濟層面的影響
- 競爭與展望
- 心臟病治療方法之解說
第4章 專訪專家
第5章 企業資料
Cardiovascular Diagnostics: Key Developments in Technologies and Markets addresses the latest trends and developments in cardiovascular imaging and in vitro diagnostic techniques that will impact the market and the delivery of healthcare.
Cardiovascular diseases continue to be an enormous medical and cost burden on the health care system. As the rapidly aging population drives an increase in the incidence and prevalence of heart disease, the need for early detection and intervention will escalate dramatically. Cardiovascular Diagnostics: Key Developments in Technologies and Markets describes how the evolution of imaging technologies and discovery of new biomarkers is leading to continuous improvement in the ability to diagnose disease, monitor drug treatment, and identify patients at risk for cardiovascular events, such as heart attack and stroke.
The following market trends and developments, as well as the companies competing in each area, are evaluated:
- A high clinical need exists for non-invasive angiography procedures to assess coronary artery blockages. The report evaluates new CT scan technology and its potential to deliver billions of dollars in savings to the health care system along with a lower risk of complications for the patient.
- Emerging cardiovascular biomarkers that will allow for better detection of patients at risk for developing coronary artery disease, including C-Reactive Protein, as well as a number of different inflammatory and ischemia biomarkers that are under investigation for faster diagnosis of myocardial infarction and to rule out acute coronary syndrome in patients presenting with chest pain.
- New radiopharmaceuticals agents being developed for cardiovascular nuclear medicine that promise to improve diagnosis.
- Advances in magnetic resonance (MR) imaging and other imaging modalities used in cardiovascular diagnostics.
- Early-stage developments in imaging unstable or ruptured plaque deposits in arteries.
- The emerging trend of cardio-theranostics, the pairing of a laboratory test with a cardiovascular drug.
Executive Summary
- Cardiovascular Imaging: Trends and Implications
- In Vitro Cardiovascular Diagnostics: Trends and Implications
Chapter 1. Background Trends in Cardiovascular Disease
- 1.1 Cardiovascular Disease Statistics
- Coronary Heart Disease
- Congestive Heart Failure
- Hypertension
- Stroke
- Cardiac Arrhythmias
- Other Cardiovascular Disease
- 1.2 Prospects for Cardio-Theranostics
Chapter 2. Cardiovascular Imaging
- 2.1 Ultrasound
- Competition
- Market Trends and Developments
- 2.2 Magnetic Resonance
- Competition
- Market Trends and Developments
- 2.3 Computed Tomography
- Competition
- Market Trends
- 2.4 Nuclear Medicine
- SPECT Imaging
- -Competition and Market Trends
- PET Imaging
- -Competition and Market Trends
Chapter 3. Biomarkers for Cardiovascular Diagnostics
- 3.1 Biomarkers for Determining Risk in Coronary Artery Disease (CAD)
- Description of Biomarkers for Risk of CAD
- -C-Reactive Protein
- -Lp-PLA2
- -Homocysteine
- -LDL Subclasses and Particle Size
- -Lipoprotein (a)
- -Apolipoprotein A and Apolipoprotein B
- Medical and Economic Impact
- Competition and Outlook
- 3.2 Biomarkers For Diagnosis of Acute Coronary Syndrome
- Description of Current Markers for Acute Coronary Syndrome
- -Creatine Kinase MB Isoenzymes (CK-MB)
- -Troponin I and Troponin T
- -Myoglobin
- -Heart Fatty Acid Binding Proteins
- -Ischemia-Modified Albumin
- Potential Future Biomarkers for Acute Coronary Syndrome
- -Blood Choline
- -CD40 Ligand
- -Chemoattractant Biomarkers
- -Glutathione Peroxidase 1
- -Myeloperoxidase
- -Pregnancy-Associated Plasma Protein-A
- -Serum Deoxyribonuclease I Activity
- -Unbound Free-Fatty Acids
- Medical and Economic Impact
- Competition and Outlook
- Biomarkers for Congestive Heart Failure
- -Medical and Economic Impact
- -Competition and Outlook
- 3.4 Thrombosis Markers
- Description of Biomarkers and Genetic Markers
- -D-Dimer
- -Factor V Leiden
- -Prothrombin Factor II (PT 20210A)
- -Methylene-tetra-hydro-folate-reductase (MTHFR) Gene
- -Plaminogen Activator Inhibitor-1
- Medical and Economic Impact
- Competition and Outlook
- 3.5 Potential Future Markers for Stroke
- Description of Potential Stroke Markers
- -Neuron-Specific Enolase
- -S-100B
- -Matrix Metalloproteinases
- -Stroke Panel
- Medical and Economic Impact
- Competition and Outlook
- 3.6 Cardio-Theranostics
- Pharmacogenetics
- -Cytochrome P450
- -CYP2D6
- -CYP2C9
- -Cholesterol Ester Transfer Protein
- -Angiotensin-Converting Enzyme Gene
- -Beta-1 and Beta-2 Adrenergic Receptor Gene
- -N-Acetyltransferase-2 Gene
- -Platelet Fc-Gamma-Receptor Gene
- -Alpha-Adducin Gene Variant
- -Apolipoprotein E Genotyping
- Other Cardio-Theranostics
- -Antiplatelet Drug Testing
- -Aspirin Resistance Test
- Medical and Economic Impact
- Competition and Outlook
Chapter 4. Expert Interviews
- Cardiovascular In Vitro Diagnostic Interviews
- -Alberto Abate, bioMérieux
- -Kenneth F. Buechler, PhD, Biosite
- -Hans-Juergen Loyda, Roche Diagnostics
- -David Ludvigson, Nanogen, Inc.
- --Biomarker Tests
- --Genomic Testing
- -- New Biomarkers
- Cardiovascular Imaging Interviews
- -James Kronauge, PhD, Molecular Insight
- -Gregg Mayer, EPIX Pharmaceuticals
Chapter 5. Company Profiles
- Abaxis
- Abbott Diagnostics
- Atherotech
- Bayer HealthCare
- Beckman Coulter
- Berlex Laboratories, Inc.
- bioMérieux SA
- Biosite
- Bracco Diagnostics
- Bristol Myers Squibb Medical Imaging
- Cholestech
- Dade Behring
- Diagnostic Products Corp. (DPC)
- GE Healthcare
- Instrumentation Laboratory
- International Technidyne Corp (ITC)
- Ischemia Technologies
- LipoScience
- Mallinkrodt
- Nanogen
- Ortho Clinical Diagnostics
- Philips Medical Systems
- Response Biomedical
- Roche Diagnostics
- Siemens Medical Solutions
- Spectral Diagnostics
- Sysmex
- Third Wave Technology
- References
- Index
|
